RANKL Inhibition to Combat Sarcopenia in Hip Fracture Patients
Key claim: A pragmatic randomized, double-blind, active-controlled trial will test whether RANKL inhibition treats sarcopenia in patients with hip fracture.
Abstract
The objective of this study is to conduct a pragmatic, randomized, double-blind, active-controlled trial to assess the efficacy of receptor activator of nuclear factor-kB ligand (RANKL) inhibition in the treatment of sarcopenia in hip fractures.
Why this matters
Sarcopenia intervention research has been dominated by resistance training plus nutrition, with pharmacologic candidates mostly at the mechanism or repurposing stage. A pragmatic double-blind RCT testing a RANKL-pathway drug specifically for sarcopenia in hip fracture patients puts a bone-axis therapy into a muscle endpoint in exactly the acute frail-surgical population where both bone and muscle collapse together. Protocol-only for now — the interpretive question is whether shared osteo-muscular biology yields functional gains beyond bone protection.